Manganese chelate isomers

The manganese chelate isomers synthesized through stereoselective solution, the problem of insufficient stability of manganese chelate in the physiological environment is solved, and its stability in vivo and metal transfer rate is significantly improved. It is suitable for high-efficiency MRI contrast agents development.

CN119080772APending Publication Date: 2024-12-06GE HEALTHCARE AS
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411197701.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-09-03
Filing Date
2020-09-03
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing manganese (II) chelates have low stability in the physiological environment and are difficult to use as effective MRI contrast agents, especially compared with gadolinium chelates.

Method used

A new manganese chelate compound has been developed, with a specific structure of the compound of formula IA and its salt or solvate, and its isomers are obtained by stereoselective synthesis, such as (R,R)-Mn chelate- 5. (S,S)-Mn chelate-5, (R,S)-Mn chelate-5, etc., optimize their stability and metal transfer rate in vivo.

Benefits of technology

The manganese chelate isomers synthesized through stereoselectively significantly improve the stability of manganese chelates and the metal transfer rate in vivo, reduce the release of manganese ions, extend the residence time in vivo, and improve MRI imaging performance of agent.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119080772A_ABST
    Figure CN119080772A_ABST
Patent Text Reader

Abstract

The invention relates to manganese chelate isomers. The present invention relates to isomers of chelate compounds and their use as contrast agents in magnetic resonance imaging (MRI) procedures.
Need to check novelty before this filing date? Find Prior Art

Description

This application is a divisional application of the invention patent application with application date of September 3, 2020, application number 202080061544.2, and invention name “Manganese chelate isomers”. Technical Field

[0001] The present invention relates to isomers of chelate compounds and their use as contrast agents in magnetic resonance imaging (MRI) procedures. Background Art

[0002] MRI is a medical imaging technique in which regions of the body are visualized by the nuclei (especially hydrogen nuclei) of selected atoms. The MRI signal depends on the environment surrounding the visualized nuclei and their longitudinal and transverse relaxation times T1 and T2. Therefore, in the case where the visualized nuclei are protons, the MRI signal intensity will depend on factors such as proton density and the chemical environment of the protons. Contrast agents can be used in MRI to improve imaging contrast. They work by affecting the T1, T2 and / or T2* relaxation times, and thereby affect the contrast in the image.

[0003] It is known that paramagnetic contrast agents can change the T1, T2 and / or T2* relaxation times, and this effect can be optimized by structural changes of the paramagnetic metal chelate. Of particular importance is the presence and residence time of water molecules bound to the paramagnetic ions and the rotational correlation time of the contrast agent. The presence and residence time of water molecules bound to the paramagnetic ions can be adjusted by selecting the paramagnetic ions and the chelating moiety. The rotational correlation time can be adjusted by changing the size of the contrast agent.

[0004] When paramagnetic chelates are used as contrast agents for MRI, their solubility in water is also an important factor, since they are administered to patients in relatively large doses. Highly water-soluble paramagnetic chelates require lower injection volumes and are therefore easier to administer to patients and cause less discomfort. Water-soluble paramagnetic chelates (i.e., complexes of a chelating agent and a paramagnetic metal ion) are well known, for example the commercially available gadolinium chelate Omniscan TM (GE Healthcare), Dotarem TM (Guerbet), Gadavist TM (Bayer) and Magnevist TM (Bayer). Due to their low molecular weight, they are rapidly distributed into the extracellular space (ie, blood and interstitium) when administered into the vasculature. They are also cleared from the body relatively quickly.

[0005] The key property of MRI chelate compounds is to retain paramagnetic ions in the chelate structure as much as possible. Paramagnetic ions released from the chelate in vivo can interfere with biological pathways and potentially induce toxicity. The ability of the chelate to retain paramagnetic ions (also referred to herein as stability) is also a property that can be adjusted by the structural design of the chelating ligand portion. Of particular interest is kinetic stability, which is measured as a dissociation half-life, which indicates the degree of inertness to a changed chemical environment (i.e., endogenous ions).

[0006] As can be understood from the commercially available agents and the focus of the prior art, gadolinium is the most widely used paramagnetic metal ion for MRI chelates due to its favorable relaxivity properties. The concept of "relaxivity" of an MRI agent is well known to those skilled in the art and refers to the ability of a magnetic compound to increase the relaxation rate of the spins of surrounding water protons. Relaxivity is used to improve the contrast of MR images and to study specific areas of tissue where contrast agents diffuse better or to perform functional MRI. The relaxivity of an MRI agent depends on the molecular structure and kinetics of the complex. The relaxivity depends on the temperature, field strength and the substance in which the contrast agent is dissolved.

[0007] For gadolinium chelates to be used as contrast agents, stability of the paramagnetic ions within the chelate structure is desirable. It would therefore be desirable to identify new gadolinium chelates with a higher level of stability, particularly in a physiological environment.

[0008] Manganese (II) ions are paramagnetic species with high spin numbers and long electron relaxation times, and the potential of high relaxation efficiency contrast agents based on manganese (II) has been reported in the literature (Toth, E, Advances in Inorganic Chemistry, 2009, 61 (09), 63-129). However, some manganese (II) chelates developed to date have proven to be much less stable than the corresponding gadolinium chelates. For example, the manganese chelate of DOTA (MnDOTA) is several hundred times less stable than the corresponding gadolinium complex Gd-DOTA (Drahos, B; Inorganic Chemistry, 2012 (12), 1975-1986).

[0009] WO2011 / 073371, issued to Andreas Meijer on June 23, 2011, describes a molecular design that favors high chelate stability and high relaxivity. This makes these compounds very suitable for use as MRI contrast agents. Exemplary compounds of WO2011 / 073371 have the following structures: WO2017 / 220610, issued to Andreas Meijer et al. on December 28, 2017, describes manganese chelates suitable for use as contrast agents and providing superior properties over other known manganese-based contrast agents. The manganese chelates of WO2017 / 220610 include compounds of formula (1): or a salt or solvate thereof, wherein: Each R 1 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 an aryl, or carbohydrate moiety; Each R 2 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 Alkyl or hydrogen; R 3 Selected from C 1-3 Alkyl or -(CH 2 ) m -C(=O)-NR 5 R 6 , where m is an integer from 2 to 5, and R 5 and R 6 As for R 1 and R 2 defined; R 4 represents 0-3 selected from hydroxyl, C 1-6 Alkyl and C 1-6 a substituent of the hydroxyalkyl group; and, Each n is an integer from 0 to 4; And wherein the compound of formula I contains at least two hydroxyl groups.

[0010] There remains a need to develop stable manganese contrast agents suitable for use as contrast agents. Summary of the invention

[0011] The present invention relates to compounds of formula IA: or a salt or solvate thereof. In the above formula, each R 1 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6aryl, or a carbohydrate moiety. Each R 2 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 Alkyl or hydrogen. 3 Selected from C 1-3 Alkyl or -(CH 2 ) m -C(=O)-NR 5 R 6 , where m is an integer from 2 to 5, where R 5 and R 6 are independently selected from hydrogen, C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 Aryl, or a carbohydrate moiety. 4 represents 0-3 selected from hydroxyl, C 1-6 Alkyl and C 1-6 Substituents of the hydroxyalkyl group. Each n is an integer of 0-4.

[0012] In one embodiment, the invention relates to a composition comprising a compound of formula IA or a salt or solvate thereof and a pharmaceutically acceptable excipient. In one embodiment, the composition lacks a detectable amount of a compound of formula IB: Each R 1 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 aryl, or a carbohydrate moiety. Each R 2 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 Alkyl or hydrogen. 3 Selected from C 1-3 Alkyl or -(CH 2 ) m -C(=O)-NR 5 R 6 , where m is an integer from 2 to 5, where R 5 and R 6 are independently selected from hydrogen, C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 Aryl, or a carbohydrate moiety.4 represents 0-3 selected from hydroxyl, C 1-6 Alkyl and C 1-6 Substituents of the hydroxyalkyl group. Each n is an integer of 0-4.

[0013] In one embodiment, the invention is directed to a method of imaging a patient comprising administering a contrast agent or contrast agent composition followed by obtaining an MRI image of the patient.

[0014] In one embodiment, the present invention relates to a process for preparing the above imaging agent. The process may involve enantioselective synthesis or isomerization of a compound of formula (1A) to a compound of formula (1B). BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The predicted stereoisomers of Mn chelate-5 are shown.

[0016] Figure 2 HPLC chromatograms are shown for (a) Mn chelate-5 synthesized without stereochemical control, (b) (R,S)-Mn chelate-5, (c) (R,R)-Mn chelate-5, (d) (S,S)-Mn chelate-5, and (e) (S,R)-Mn chelate-5.

[0017] Figure 3 Shown is the percentage of dechelation of the Mn chelate-5 stereoisomer in human serum.

[0018] Figure 4 Show that when in xs.ZnCl 2 Remaining Mn chelate-5% as a function of time for (a) (R,R)-Mn chelate-5 (diamonds), (b) (S,S)-Mn chelate-5 (squares), (c) (S,R)-Mn chelate-5 (circles), and (d) (R,S)-Mn chelate-5 (triangles) when incubated in the presence of .

[0019] Figure 5 Shown are the %ID (injected dose) / organ 7 days after injection of a 0.62 mmol Mn chelate-5 / kg dose containing ∼30 μmol Mn-54 chelate-5, (a) synthesized without stereochemical control (solid bars), (b) a 1:1 mixture of (R,R & S,S)-Mn chelate-5 isomers (dashed bars), and (c) (R,S)-Mn chelate-5 (square bars).

[0020] Figure 6 The structure of Mn chelate-10 is shown.

[0021] Figure 7 The structure of Mn chelate-15 is shown.

[0022] Figure 8 The % Mn chelate remaining as a function of time is shown for (R,S)-Mn Chelate-5 (circles), a 1:1 mixture of (R,R & S,S)-Mn Chelate-5 isomers (X), Mn Chelate-10 isomer pool A (triangles), and Mn Chelate-10 isomer pool B (diamonds).

[0023] Fig. 9 Shown is a synthetic route to an isomerically pure chelate according to an embodiment of the present invention.

[0024] Fig.10 is an example chromatogram showing the separation of manganese-containing proteins from the intact chelate. DETAILED DESCRIPTION

[0025] In order to more clearly and concisely describe and point out the subject matter of the claimed invention, definitions and exemplary embodiments of specific terms used throughout the specification and claims are provided below.Any exemplification of specific terms herein should be considered as non-limiting examples.

[0026] The term "comprising" or "comprises" has its conventional meaning throughout this application and implies that the agent or composition must have the listed essential features or components, but others may be present in addition. The term "comprising" includes "consisting essentially of" as a preferred subset, which means that the composition has the listed components without the presence of other features or components.

[0027] According to the invention, "salts" include physiologically acceptable acid addition salts, such as those derived from inorganic acids (e.g., hydrochloric acid, hydrobromic acid, phosphoric acid, metaphosphoric acid, nitric acid and sulfuric acid) and those derived from organic acids (e.g., tartaric acid, trifluoroacetic acid, citric acid, malic acid, lactic acid, fumaric acid, benzoic acid, glycolic acid, gluconic acid, succinic acid, methanesulfonic acid and p-toluenesulfonic acid).

[0028] According to the present invention, suitable "solvates" are selected from ethanol, water, saline, physiological buffers and glycols.

[0029] The term "alkyl", alone or in combination, refers to a radical having the general formula C n H 2n+1 Examples of such groups include methyl, ethyl and isopropyl.

[0030] The term "hydroxy" refers to the group -OH.

[0031] The term "hydroxyalkyl" refers to an alkyl group as defined above containing one or more hydroxy substituents as defined above.

[0032] The term "aryl" refers to a functional group or substituent derived from an aromatic ring (usually an aromatic hydrocarbon), examples of which include phenyl and pyridyl. In one embodiment, the aryl group of the present invention is an aromatic 6-membered ring having 0-3 heteroatoms selected from O, N and S.

[0033] The term "halogen" or "halo" refers to a substituent selected from fluorine, chlorine, bromine or iodine.

[0034] The term "hydroxy" refers to the group -OH.

[0035] The term "chelate moiety" refers to a substituent for a metal chelate, wherein the term "metal chelate" refers to a coordination complex, wherein the metal ion is bonded to the surrounding array of the molecule or anion contained in the chelate ligand." chelate ligand" is defined in this article as an organic compound that can form a coordination bond with a paramagnetic metal ion by two or more donor atoms. In typical chelate ligands that are applicable to the present invention, 2-6 (and preferably 4-6) metal donor atoms are arranged so as to obtain 5 or 6 rings (by having a carbon atom or a non-coordinated heteroatomic non-coordinated main chain connecting the metal donor atom). The example of the suitable donor atom type of the metal ion being a paramagnetic metal ion includes amine, mercaptan, amides, oxime and phosphine. In one embodiment, the metal ion is manganese.

[0036] In one aspect, the invention relates to compounds of formula IA: or a salt or solvate thereof. In this formula, each R 1 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 aryl, or a carbohydrate moiety; each R 2 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 Alkyl or hydrogen; R 3 Selected from C 1-3 Alkyl or -(CH 2 ) m -C(=O)-NR 5 R 6 , where m is an integer from 2 to 5, where R 5 and R 6 are independently selected from hydrogen, C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6Aryl, or carbohydrate moiety; R 4 represents 0-3 selected from hydroxyl, C 1-6 Alkyl and C 1-6 substituents of the hydroxyalkyl group; and, each n is an integer of 0-4.

[0037] The following method illustrates the stereoselective synthesis of the (R,R) and (S,S) isomers of Mn chelate-5. (R,R)-Mn chelate-5 was synthesized from the deprotected 2-arm cyclic chelate (Compound III) via dialkylation with (S)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester to afford the protected (R,R)-Mn 2-arm C5 chelate (Compound V). The protected (R,R)-Mn 2-arm C5 chelate was then deprotected under acidic conditions, Mn chelated, and amino alcohol (D-glucosamine) coupled to afford (R,R)-Mn chelate-5. (S,S)-Mn chelate-5 was synthesized from the deprotected 2-arm cyclic chelate (Compound III) via dialkylation with (R)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester to afford the protected (S,S)-Mn 2-arm C5 chelate (Compound VI). The (S,S)-Mn 2-arm C5 chelate was converted to (S,S)-Mn chelate-5 using the method described above for the synthesis of (R,R)-Mn chelate-5.

[0038] The following method illustrates the stereoselective synthesis of the (S,R) and (R,S) isomers of Mn chelate-5. (S,R)-Mn chelate-5 and (R,S)-Mn chelate-5 were synthesized from the deprotected 2-arm cyclic chelate via monoalkylation with (S)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester followed by alkylation with (R)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester to give (R,S)-Mn 2-arm C5 chelate (Compound VII). The (R,S)-Mn 2-arm C5 chelate was then deprotected under acidic conditions and Mn chelated to give a mixture of (S,R)-Mn 2-arm C5 chelate and (R,S)-Mn 2-arm C5 chelate. The mixture of (S,R)-Mn 2-arm C5 chelate and (R,S)-Mn 2-arm C5 chelate was then coupled with amino alcohol (D-glucosamine) to give a mixture of (S,R)-Mn chelate-5 and (R,S)-Mn chelate-5, which was then reacted via C 18Chromatographic separation. In addition, the (R,S)-Mn chelate-5 chelate was synthesized by heating a mixture of (S,R)-Mn 2-arm C5 chelate and (R,S)-Mn 2-arm C5 chelate at 90°C until the isomerization of (S,R)-Mn 2-arm C5 chelate to (R,S)-Mn 2-arm C5 chelate was complete, and then the (R,S)-Mn 2-arm C5 chelate was coupled with an amino alcohol (D-glucosamine) to obtain (R,S)-Mn chelate-5. As can be appreciated by those skilled in the art, the methods described for the stereoselective synthesis of isomers of Mn chelate-5 can be applied to the stereoselective synthesis of compounds described by Formulas IA and IB.

[0039] Mn chelate-5 was synthesized without stereochemical control at the position of attachment to the macrocycle. In the absence of stereochemical control, four isomers are expected, such as Figure 1 As shown. (S,R) and (R,S) isomers can be interconverted via dechelation and rechelation of the metal. The R and S designations represent the stereochemistry at the point of attachment to the macrocycle.

[0040] Figure 2 2a shows the results of HPLC analysis of Mn chelate-5 synthesized without stereochemical control. Fig. 9 As described in, (S,S)-Mn chelate-5 and (R,R)-Mn chelate-5 were synthesized enantioselectively. The results from HPLC analysis of (R,R)-Mn chelate-5 are shown in Figure 2 HPLC analysis of (S,S)-Mn chelate-5 is shown in Figure 2 In 2D. Fig. 9 The enantioselective synthesis of (R,S)-Mn chelate-5 and (S,R)-Mn chelate-5 was carried out as described in . The results from the HPLC analysis of (R,S)-Mn chelate-5 are shown in Figure 2 2b, and the results from HPLC analysis of (S,R)-Mn chelate-5 are shown in Figure 2 2e.

[0041] In the presence of 100-fold excess Zn (200 mM ZnCl 2 , in 15 mM ammonium formate, pH=4, at 40°C), and the transmetallation stability of Mn chelate-5 with Zn was evaluated with 2 mM Mn chelate-5 at pH=4. Figure 3The remaining Mn chelate-5% is shown as a function of time for (R,R)-Mn chelate-5 (diamonds), (S,S)-Mn chelate-5 (open squares), (S,R)-Mn chelate-5 (circles), and (R,S)-Mn chelate-5 (triangles). Surprisingly, Figure 3 The data in show that the metal transfer rate of the (R,S)-Mn chelate-5 isomer is significantly slower, while the metal transfer rate of the (S,R)-Mn chelate-5 isomer is significantly faster, indicating differences in the strength of Mn chelation as a function of chelate stereochemistry. The stability of the Mn chelate-5 stereoisomers in human serum was evaluated in vitro by monitoring the transfer of Mn from the chelate to blood proteins using a method that combines size exclusion chromatography with on-line detection of manganese-containing species by ICP-MS. Figure 3 The percentage of dechelation during a total incubation time of 2 days at 37° C. is shown. According to the results obtained in the Zn transmetallation studies, there is a significant difference between the (S,R)-Mn chelate 5 isomer (upper curve, least stable) and the (R,S)-Mn chelate 5 isomer (lower curve, most stable).

[0042] via 54 The in vivo stability of the different isomeric pools was evaluated by the biodistribution of Mn radioactivity, since it is known that Mn released in vivo is retained in the brain, bone, and liver. 54 Mn-labeled materials. The amount of Mn released in vivo was evaluated for Mn chelate-5 synthesized without stereochemical control, a 1:1 mixture of (R,R)-Mn chelate-5 and (S,S)-Mn chelate-5 isomers, and (R,S)-Mn chelate-5 isomer pool B. A 1:1 mixture of (R,R)-Mn chelate-5 and (S,S)-Mn chelate-5 isomers was chosen because the 2 isomers are expected to have comparable stabilities based on their similar metal transfer rates. Rats were treated with 50 μCi of 4% Mn in water containing ∼30 μCi 54 Mn chelate-5 was administered at 0.62 mmol Mn chelate-5 / kg. The animals were killed 7 days after injection, the organs of interest were collected, and the remaining Mn in the organs was measured using a gamma counter. 54 Mn. Figure 4 It is shown that the injection contains ~30μmol 54 Plot of %ID (injected dose) / organ after 7 days of 0.62 mmol Mn chelate-5 / kg dosing of Mn chelate-5. Columns containing dashed lines represent %ID / organ at or below the limit of detection studied. Statistical comparisons of %ID for each organ were summarized as p-values ​​using one-way ANOVA Games-Howell comparisons or 2-way t-tests as appropriate, as shown for each organ.

[0043] Surprisingly, Figure 4 The data in show that significantly less Mn remained in vivo after injection of (R,S)-Mn chelate-5 for up to 7 days compared to a 1:1 mixture of (S,S)-Mn chelate-5 and (R,R)-Mn chelate-5 or Mn chelate-5 synthesized without stereochemistry control in brain and bone, consistent with less Mn release in vivo. This is consistent with the Zn metal transfer data and further supports the conclusion that the strength of Mn chelation is a function of chelate stereochemistry. This is further supported by the higher levels of Mn detected in the kidney for (R,S)-Mn chelate-5, as more intact Mn chelate-5 will pass through the kidney.

[0044] Since Mn chelate-5 contains 10 additional stereocenters in the glucosamine side chain in addition to the two stereocenters α at the macrocyclic α position, racemic 3-amino-1,2-propanediol and C 18 Synthesis of Mn chelate-10( without stereochemical control by chromatography Figure 5 ), Mn chelate-10 isomer pool A and Mn chelate-10a isomer B were obtained. Using the above conditions, Zn metal transfer was performed with Mn chelate-10 isomer pool A and Mn chelate-10a isomer B ( Fig. 9 ). Surprisingly, Mn chelate-10 isomer pool A, (S,S)-Mn chelate-5, and (R,R)-Mn chelate-5 transmetallate with Zn at the same ratio, and Mn chelate-10 isomer pool B and (R,S)Mn chelate-5 transmetallate with Zn at the same ratio. The data show that neither the personality of the sidearm nor the stereochemistry of the sidearm affects the strength of Mn chelation, while the stereochemistry of the macrocyclic alpha position is key in determining the stability of the Mn chelate. Based on the data presented above, it is reasonable to assume that (R,S) and / or (S,R) stereochemistry at the macrocyclic alpha position is preferred in terms of Mn chelate stability compared to (R,R) and (S,S) stereochemistry at the macrocyclic alpha position.

[0045] The following Examples Examples 1-8 describe the preparation of precursors of the present invention. Examples 9-23 describe compounds according to various embodiments of the present invention.

[0046] Example 1 Synthesis of N,N'-((methylazanediyl)bis(ethane-2,1-diyl))bis(4-methylbenzenesulfonamide) (Compound I).

[0047] Compound I Equipped with a 1L round-bottom flask with a magnetic stirring bar, N-toluenesulfonyl aziridine (49g, 248mmol) and AcN (450mL) were loaded. 41% aqueous methylamine (12mL, 121mmol) was added and stirred at ambient temperature for 36 hours. A second aliquot of N-toluenesulfonyl aziridine (1.7g, 8.62mmol) was added and stirred at ambient temperature for another 48 hours. The solvent was removed in vacuo, and the crude residue was recrystallized with EtOH to obtain 45g (87%) of the desired product as a white solid. 1HNMR (400MHz, DMSO-D6, δ) 7.68 (4H, m), 7.36 (6H, m), 2.75 (4H, t), 2.38 (6H, s), 2.22 (4H, t), 1.93 (3H, s).

[0048] Example 2 Synthesis of protected cyclic 2-arm chelate (Compound II).

[0049] Compound II A 12 L 3-neck round bottom flask equipped with a reflux condenser and a mechanical stirrer was charged with N,N'-((methylazanediyl)bis(ethane-2,1-diyl))bis(4-methylbenzenesulfonamide) (93 g, 218.5 mmol) and AcN (8.3 L). 2,6-bis(chloromethyl)pyridine (38.5 g, 218.5 mmol) was added and the resulting solution was heated at 80 °C for 16 hours. The reaction mixture was cooled to ambient temperature and the solvent was removed in vacuo until crystallization began. The resulting crystals were collected via vacuum filtration to give 86.9 g (75%) of the desired product as a white solid (ESI: m / z=530 (M+H) + ).

[0050] Example 3 Synthesis of the deprotected 2-arm cyclic chelate (Compound III).

[0051] Compound III The 1L 3-necked round-bottom flask equipped with a mechanical stirrer is equipped with a cyclic 2-arm chelate (150g, 284mmol) and the concentrated sulphuric acid (250mL, 4.69mol) of protection, and heated at 100 ℃ for 15 hours. The solution is poured into ice, and by adding the 50 % by weight NaOH aqueous solution, the pH is adjusted to 7.4, causing the formation of a white solid. Add AcN (200mL), and remove the white solid via vacuum filtration. The filtrate is evaporated to dryness, to obtain brown foam. The foam is dissolved in the water (200mL), and purified by the Amberlite A26 resin of its hydroxide form, to obtain the desired product of 61g (98%) tan solid form. 1HNMR(400MHz,AcN-D3,δ)7.56(1H,m),7.03(2H,m),3.76(4H,s),2.47(4H,m),2.19(3H,s),1.95(4H,s).

[0052] Example 4 Synthesis of protected Mn 2-arm C5 chelate (Compound IV).

[0053] Compound IV A 500 mL round bottom flask equipped with a magnetic stirring bar was loaded with the deprotected 2-arm cyclic chelate (20.0 g, 90.8 mmol) and AcN (160 mL). Diisopropylethylamine (38.7 mL, 217 mmol) and dimethyl 2-bromoglutarate (47.7 g, 199.7 mmol) were added, and the resulting solution was stirred at 65 ° C for 20 hours. Diisopropylethylamine (9.75 mL, 54.6 mmol) and dimethyl 2-bromoglutarate (11.8 g, 49.4 mmol) were added, and the resulting solution was stirred at 65 ° C for another 19 hours. The solvent was removed in vacuo to leave a red oil. The oil was then dissolved in water (300 mL) and washed with EtOAc (300 mL). The EtOAc layer was then extracted with water (2×50 mL) and combined with the initial water layer, and the water was removed in vacuo to leave a red oil, which was used without further purification.

[0054] Example 5 Synthesis of protected (R,R)-Mn 2-arm C5 chelate (Compound V).

[0055] Compound V A 50 mL round bottom flask equipped with a magnetic stir bar was charged with the deprotected 2-arm cyclic chelate (1.01 g, 4.58 mmol), potassium carbonate (1.58 g, 11.5 mmol) and AcN (10 mL). (S)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester (Levy, SG et al., Org. Proc. Res. Dev. 2009, 13, 535-542) (2.60 g, 6.98 mmol) was dissolved in AcN (2 mL) and then added to the stirred suspension. The mixture was heated in an oil bath at 50° C. for 21 hours. Additional amounts of (S)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester (1.71 g, 4.59 mmol in 2 mL of AcN) and potassium carbonate (317 mg, 2.29 mmol) were added and heating was continued for an additional 47 hours. The reaction was then cooled to room temperature and filtered through a 0.45 μm PTFE filter. The solid was rinsed with acetonitrile (5×5 mL) and the combined filtrates were concentrated under reduced pressure, which provided a red oil that was continued without further purification (ESI: m / z=774 (M+H) + ). Specific rotation: [α] 27 D = +12.1° (c = 0.00404, acetonitrile); 1 H NMR (CDCl 3 ,500MHz)δ1.40-1.45(m,10H),1.49(s,9H),1.55-1.64(m,1H),1.65-1.73(m,1H),1.85-1.95(m,2H),1.95-2.04(m,1 H),2.04-2.10(m,2H),2.83-2.87(m,3H),2.93-2.98(m,1H),3.05-3.28(m,7H),3.57(d,J=17.4Hz,1H),3.70(d,J=16. 9Hz,1H),4.00(d,J=16.9Hz,1H),4.03-4.14(m,2H),4.25(d,J=17.6Hz,1H),4.84-4.98(m,4H),6.93(d,J=7.6Hz,1H), 6.99(d,J=7.6Hz,1H),7.15-7.20(m,2H),7.20-7.23(m,2H),7.28-7.34(m,6H),7.49(t,J=7.6Hz,1H),11.45(bs,1H); 13 C NMR (CDCl 3,125MHz)δ25.5,26.6,28.3,28.4,30.4,30.6,33.9,46.7,52.9,53.6,54.3,54.7,57.7,66.3,66.5,66.8,67.9,82. 5,82.6,120.2,120.6,126.0,128.5,128.6,128.7,135.7,135.8,138.5,159.8,160.9,170.7,171.3,172.1,172.2.

[0056] Example 6 Synthesis of protected (S,S)-Mn 2-arm C5 chelate (Compound VI).

[0057] Compound VI A 10 mL round bottom flask equipped with a magnetic stirring bar was charged with the deprotected 2-arm cyclic chelate (0.210 g, 0.953 mmol), potassium carbonate (0.329 g, 2.38 mmol) and AcN (6 mL). (R)-1-tert-butyl 2-(methylsulfonyloxy) pentanedioic acid 5-benzyl ester (prepared from D-glutamic acid: Levy, SG et al., Org. Proc. Res. Dev. 2009, 13, 535-542) (0.888 g, 2.38 mmol) was dissolved in AcN (2 mL) and then added to the stirred suspension. The mixture was heated in an oil bath at 50° C. for 67 hours. The reaction was then cooled to room temperature and concentrated under reduced pressure. The residue was distributed between water and dichloromethane (20 mL each). The layers were separated and the aqueous layer was extracted with dichloromethane (2×10 mL). The combined organics were back extracted with water (2 x 20 mL) and then dried over anhydrous sodium sulfate. The dried organic layer was then filtered through a 0.45 μm PTFE filter and the filtrate was concentrated under reduced pressure to afford a yellow oil which was continued without further purification (ESI: m / z = 774 (M+H) + ).

[0058] Example 7 Synthesis of protected (R,S)-Mn 2-arm C5 chelate (Compound VII).

[0059] Compound VII A 10 mL round bottom flask equipped with a magnetic stirring bar and a nitrogen inlet was loaded with the deprotected 2-arm cyclic chelate (278 mg, 1.26 mmol) and isopropanol (4 mL). Diisopropylethylamine (522 μL, 3.07 mmol) was added, followed by (S)-1-tert-butyl 2-(methylsulfonyloxy)pentanedioic acid 5-benzyl ester (prepared by L-glutamic acid: Levy, SG et al., Org. Proc. Res. Dev. 2009, 13, 535-542) (407 mg, 0.87 mmol) and additional isopropanol (1 mL). The resulting solution was placed in nitrogen and heated in an oil bath at 50° C. for 48 hours. Add additional amounts of (S)-1-tert-butyl 2-(methylsulfonyloxy) pentanedioic acid 5-benzyl ester (222mg, 0.596mmol) and diisopropylethylamine (215μL, 1.26mmol), and continue heating for another 21 hours. The reaction is cooled to room temperature and concentrated under reduced pressure. The residue is diluted with 15mL dichloromethane and 30mL water. The layers are separated, and the water layer is extracted with 15mL dichloromethane. The combined organic matter is washed with 30mL water and then dried over sodium sulfate. The dried organic matter is filtered through a #1 filter, and the resulting filtrate is concentrated under reduced pressure. Use gradient elution (AcN / 2mMHCl, 10:90 to 80:20) at C 18 The residual material was purified on column to give 260 mg (43%) of the (R)-monoalkylated intermediate (ESI: m / z = 497 (M+H) + ). A 10 mL round bottom flask equipped with a magnetic stir bar and a nitrogen inlet was charged with the monoalkylated intermediate (260 mg, 0.524 mmol) and acetonitrile (5 mL). Potassium carbonate (219 mg, 1.58 mmol) was added, followed by (R)-1-tert-butyl 2-(methylsulfonyloxy) pentanedioic acid 5-benzyl ester (prepared from D-glutamic acid: Levy, SG et al., Org. Proc. Res. Dev. 2009, 13, 535-542) (252 mg, 0.676 mmol). The resulting solution was placed in nitrogen and heated in an oil bath at 50° C. for 48 hours. An additional amount of (R)-1-tert-butyl 2-(methylsulfonyloxy) pentanedioic acid 5-benzyl ester (97 mg, 0.260 mmol) was added and heating was continued for another 48 hours. The reaction was cooled to room temperature, diluted with acetonitrile, and filtered through a 0.45 μm filter. The yellow filtrate was concentrated under reduced pressure. The residue was dissolved in 1:1 acetonitrile:water (4 mL) and eluted using a gradient (AcN / 2 mM HCl, 10:90 to 80:20) at C. 18 Purification on column to give 310 mg (76%, 32% for two steps) of the desired product (ESI: m / z=774 (M+H) + ); specific rotation: [α]24 D = +1.9° (c = 0.044, acetonitrile); 1 H NMR (CDCl 3 ,500MHz)δ1.38(s,18H),1.37-1.45(m,2H),1.69-1.80(m,4H),1.80-1.89(m,2H) ,2.63(bs,3H),2.89-3.02(m,4H),3.03-3.08(m,2H),3.08-3.14(m,2H),3.47(d,J =17.5Hz,2H),3.96(bs,2H),4.15(d,J=17.5Hz,2H),4.79(s,4H),6.90(d,J=7.5Hz ,2H),7.03-7.08(m,4H),7.14-7.19(m,6H),7.41(t,J=7.5Hz,1H),11.83(bs,1H); 13 C NMR (CDCl 3 ,125MHz)δ26.1,27.8,28.0,30.0,52.1,52.7,53,4,66.0,67.4,82.0,119.8,128.2,128.3,135.3,138.6,160.4,170.9,171.8.

[0060] Example 8 Synthesis of deprotected (R,R)-Mn 2-arm C5 chelate (Compound VIII).

[0061] Compound VIII A 100mL round-bottom flask equipped with a magnetic stirring bar, a reflux condenser and a nitrogen inlet was loaded with protected (R, R)-Mn2-arm C5 chelate (3.64 g, 4.71 mmol) and dioxane (20 mL). 1M HCl (20 mL, 20.0 mmol) was added, and the mixture was placed under a nitrogen atmosphere and heated to 50 ° C. After 5 days, a concentrated HCl solution (1.7 mL, 20.4 mmol) was added, and heating was continued. After 3 days, the reaction was cooled to room temperature, and the solution was extracted with ethyl acetate (2 × 25 mL). The pH of the resulting water layer was adjusted to ~ 8 using KOH, and the solution was concentrated under reduced pressure. Methanol (25 mL) was added to the residue, and the mixture was stirred. The resulting slurry was filtered through a 0.45 μm PTFE filter. The filtrate was concentrated under reduced pressure to provide a brown foam, which was continued without further purification.

[0062] Example 9 Synthesis of deprotected (S,S)-Mn-2-arm C5 chelate (Compound IX).

[0063] Compound IX A 100 mL round-bottom flask equipped with a magnetic stirring bar, a reflux condenser, and a nitrogen inlet was loaded with protected (S, S)-Mn2-arm C5 chelate (0.713 g, 0.922 mmol) and dioxane (5 mL). Water (3.75 mL) was added, followed by concentrated HCl (1.25 mL, 15.0 mmol), and the mixture was placed under a nitrogen atmosphere and heated to 50 ° C. After 30 hours, the reaction was cooled to room temperature, and the solution was extracted with ethyl acetate (2×10 mL). The combined organic extracts were back-extracted with water (10 mL). The pH of the resulting aqueous layer was adjusted to ~8 with KOH pellets, and the solution was concentrated under reduced pressure. Methanol (25 mL) was added to the residue, and the mixture was stirred. The resulting slurry was filtered through a 0.45 μm PTFE filter. The filtrate was concentrated under reduced pressure to provide the desired product, which was continued without further purification (ESI: m / z=481 (M+H) + ).

[0064] Example 10 Synthesis of deprotected (R,S)-Mn 2-arm C5 chelate (Compound X).

[0065] Compound X A 10 mL round bottom flask equipped with a magnetic stirring bar, a reflux condenser and a nitrogen inlet was charged with the protected (R, S)-Mn2-arm C5 chelate (189 mg, 0.245 mmol) and dioxane (2.5 mL). Water (1.25 mL) was added, followed by concentrated HCl (1.25 mL), and the mixture was placed under a nitrogen atmosphere and heated to 50 ° C for 40 hours. The reaction was cooled to room temperature, and the solution was diluted with water (15 mL) and ethyl acetate (10 mL). The layers were separated, and the water layer was extracted with ethyl acetate (2×10 mL). The pH of the resulting water layer was adjusted to ~7 with KOH, and the solution was concentrated under reduced pressure. Methanol (25 mL) was added to the residue, and the mixture was stirred. The resulting slurry was filtered through a 0.45 μm PTFE filter. The filtrate was concentrated under reduced pressure to provide a deprotected chelate, which was continued without further purification (ESI: m / z=481 (M+H) + ).

[0066] Embodiment 11 Synthesis of Mn 2-arm C5 chelate (Compound XI).

[0067] Compound XI A 1L round-bottom flask equipped with a magnetic stirring bar was loaded with protected Mn 2-arm C5 chelate (48.7g, 90.8mmol) and water (450mL). Sodium hydroxide (29.1g, 726mmol) was added and stirred at ambient temperature for 2 hours. The reaction mixture was washed with EtOAc (250mL) and the layers were separated. The water layer was washed with EtOAc (2×100mL) again, and the water layer was collected. Manganese chloride tetrahydrate (19.6g, 99mmol) was added to the aqueous solution. The pH was adjusted to 7.1 with 6M NaOH, and stirred at ambient temperature for 17 hours, then stirred at 90°C for 2.5 hours. After cooling to ambient temperature, the pH was adjusted to 10.1 with a 50% by weight NaOH aqueous solution, and a thin brown precipitate was formed. The precipitate was removed by centrifugation at 3000rcf for 20 minutes, and the supernatant was collected and evaporated to dryness in vacuo. The residue was triturated with MeOH (127 mL) at 40° C. for 1.5 h. Insoluble white solids were removed by centrifugation at 3000 rcf for 30 min. The supernatant was evaporated to dryness in vacuo to give an off-white solid, which was purified on C18 silica gel (3% AcN in water) to give 36.8 g (75%) of the desired product as an off-white solid (ESI: m / z=534 (M+H) + ).

[0068] Example 12 Synthesis of (R,R)-Mn 2-arm C5 chelate (Compound XII).

[0069] Compound XII A 25 mL round bottom flask equipped with a magnetic stirring bar was charged with the deprotected (R,R)-Mn 2-arm C5 chelate (2.98 g, 4.71 mmol) and water (12 mL). Manganese chloride tetrahydrate (1.41 g, 7.12 mmol) was added to the aqueous solution. The pH was adjusted to 6.5 with 50% aqueous KOH and stirred at ambient temperature for 5 hours. The pH was adjusted to 10 with KOH and the mixture was stirred overnight. The mixture was filtered through a column containing diatomaceous earth (4.9 cm 2 The brown suspension was filtered through a 0.45 μm PTFE filter (20 μL x 1.8 cm). The pH of the filtrate was adjusted to 7.3 with concentrated HCl (20 μL) and the material was concentrated under reduced pressure. The residual material was combined with methanol (25 mL) and stirred. The resulting slurry was filtered through a 0.45 μm PTFE filter and the solid was rinsed several times with methanol. The filtrate was concentrated under reduced pressure and heated to 40 °C. 18The residual material was purified on a column (AcN / water) to give 1.09 g (43%) of the desired product (ESI: m / z=534 (M+H) + ).

[0070] Embodiment 13 Synthesis of (S,S)-Mn 2-arm C5 chelate (Compound XIII).

[0071] Compound XIII Using the same procedure as its diastereomer, (S,S)-Mn 2-arm C5 chelate (0.092 g, 0.17 mmol) produced 0.101 g (68%) of the expected product (ESI: m / z = 860 (M+H) + ). Specific rotation: [α] 24 D =-3.0° (c=0.018, water).

[0072] Embodiment 14 Synthesis of (R,S)-Mn 2-arm C5 chelate (Compound XIV).

[0073] Compound XIV A 5 mL round bottom flask equipped with a magnetic stirring bar was charged with the deprotected (R,S)-Mn 2-arm C5 chelate (180 mg, 0.284 mmol) and water (4 mL). Manganese chloride tetrahydrate (115 mg, 0.581 mmol) was added to the aqueous solution. The pH of the solution was adjusted from 6.0 to 6.4 with 50% KOH aqueous solution and stirred at ambient temperature for 4 days. The pH was adjusted to 10 with KOH and the mixture was stirred overnight. The mixture was filtered through a diatomaceous earth (4.9 cm 2 The brown suspension was filtered through a 0.45 μm PTFE filter (1.8 cm × 1.8 cm). The pH of the filtrate was adjusted to 7.2 with concentrated HCl (8 μL), and the material was concentrated under reduced pressure. The residual material was combined with methanol (25 mL) and stirred. The resulting slurry was filtered through a 0.45 μm PTFE filter, and the solid was rinsed several times with methanol. The filtrate was concentrated under reduced pressure and heated to 40 °C. 18 The residual material was purified on a column eluting with water to give 94 g (62%) of the desired product (ESI: m / z=534 (M+H) + ).

[0074] Embodiment 15 Synthesis of Mn chelate-5 (Compound XV).

[0075] Compound XV A 50 mL 2-neck flask equipped with a magnetic stirring bar was charged with D-glucosamine (0.713 g, 3.94 mmol) and water (19.7 mL). The pH of the resulting solution was adjusted to 7.4 with 1.0 M HCl, and Mn 2-arm C5 chelate (1.00 g, 1.87 mmol) was added, followed by EDCI-HCl (0.848 g, 4.42 mmol) and hydrated HOBt (0.121 g, 0.787 mmol). The pH was maintained at 6 by adding 1.0 M HCl or 1.0 M NaOH as required, while stirring at ambient temperature for 8 hours. D-glucosamine (0.359 g, 1.98 mmol) and EDCI-HCl (0.433 g, 2.26 mmol) were added, and the pH was maintained at 6 while stirring at ambient temperature for 16 hours. The reaction solution was evaporated to dryness in vacuo and the crude product was purified on C18 silica gel (100% water to 20% AcN in water) to give 0.782 g (48%) of the desired product as a light yellow solid (ESI: m / z=860 (M+H) + ).

[0076] Example 16 Synthesis of (R,R)-Mn chelate-5 (Compound XVI).

[0077] Compound XVI A 25 mL flask equipped with a magnetic stir bar was charged with (R,R)-Mn 2-arm C5 chelate (1.06 g, 2.04 mmol), D-glucosamine (0.833 g, 4.60 mmol), hydrated HOBt (0.016 g, 0.10 mmol) and water (8.2 mL). The pH of the resulting solution was adjusted to 6.2 with concentrated HCl. EDCI-HCl (0.924 g, 4.82 mmol) was added and the pH was maintained between 6-6.5 by adding concentrated HCl as needed while stirring at ambient temperature for 23 hours. The reaction solution was diluted with water (30 mL) and purified by passing the solution sequentially through an IR-120 (Na) ion exchange column followed by an IR-400 (Cl) ion exchange column. The column was heated at C 18 The crude product was purified on silica gel (2% AcN in water to 50% AcN in water) to give 1.42 g (81%) of the desired product as a light yellow foam (ESI: m / z=860 (M+H)+). Specific rotation: [α]26D=-19.7° (c=0.0129, water).

[0078] Embodiment 17 Synthesis of (S,S)-Mn chelate-5 (Compound XVII).

[0079] Compound XVII Using the same procedure as its diastereomer, (S,S)-Mn 2-arm C5 chelate (0.092 g, 0.17 mmol) produced 0.101 g (68%) of the expected product (ESI: m / z = 860 (M+H) + Specific rotation: [α]24D = -3.0° (c = 0.018, water).

[0080] Embodiment 18 Synthesis of (R,S)-Mn chelate-5 (Compound XVIII).

[0081] Compound XVIII A 5 mL flask equipped with a magnetic stirring bar was charged with (R,S)-Mn chelate-1a (60 mg, 0.112 mmol), D-glucosamine (50 mg, 0.276 mmol), hydrated HOBt (4.6 mg, 0.030 mmol) and water (3 mL). The pH of the resulting solution was adjusted to 6 with concentrated HCl (40 μL). EDCI-HCl (52 mg, 0.271 mmol) was added and the mixture was stirred at ambient temperature. An additional amount of EDCI (44 mg, 0.230 mmol) was added after 6 hours, an additional amount of EDCI (40 mg, 0.209 mmol) was added after 24 hours, and an additional amount of EDCI (50 mg, 0.261 mmol) was added after 30 hours. The reaction solution was diluted with water (3 mL) and purified by passing the solution sequentially through an IR-120 (Na) ion exchange column and then an IR-400 (Cl) ion exchange column. The elution was performed using a gradient (AcN / water, 0:100 to 10:90) at C 18 The crude product was purified on a column to obtain 23 mg of (S,R)-Mn chelate-5 (24%, 42% de) and 40 mg of (R,S)-Mn chelate-5 (42%, 91% de) (ESI: m / z = 860 (M+H) + ).

[0082] Embodiment 19 The (S,R)-Mn 2-arm C5 chelate isomerizes to (R,S)-Mn 2-arm C5.

[0083] A mixture of (R,S)-Mn chelate-1a and (S,R)-Mn chelate-1a (59 mg, 0.111 mmol) was dissolved in water (1 mL). The mixture was sealed in a glass vial and heated to 90°C for 42 hours. After the heating period, HPLC showed that the two peaks collapsed into one peak. (ESI: m / z=534 (M+H) + ).

[0084] Embodiment 20 (R,S)-Mn chelate-5 was synthesized from the isomerized (S,R)-Mn 2-arm C5 chelate.

[0085] To an HPLC vial containing (R,S)-Mn chelate-1a (59 mg, 0.111 mmol) and water (1 mL) was added D-glucosamine (49 mg, 0.270 mmol) and hydrated HOBt (5 mg, 0.032 mmol). The pH of the resulting solution was adjusted to 5.7 with concentrated HCl (35 μL). EDCI-HCl (53 mg, 0.276 mmol) was added, and the mixture was stirred at ambient temperature for 22 hours. More EDCI (23 mg, 0.120 mmol) was added, and the reaction was stirred for an additional 42 hours. The reaction solution was diluted with water (3 mL) and purified by passing the solution sequentially through an IR-120 (Na) ion exchange column, followed by an IR-400 (Cl) ion exchange column. A gradient elution (AcN / water, 0:100 to 10:90) was used at C 18 The crude product was purified on a column to give 12 mg (37%, 74% de) of the desired (R,S) isomer as an off-white solid (ESI: m / z = 860 (M+H) + ).

[0086] Embodiment 21 Synthesis of Mn chelate-10 (Compound XIX).

[0087] Compound XIX In a 25 mL 2-necked round-bottom flask equipped with a magnetic stir bar and a pH probe, rac-3-aminopropane-1,2-diol (0.190 g, 2.08 mmol) was dissolved in HO. 2O (10.4mL). The resulting solution was adjusted to pH 7.1 with 1.0M HCl, and Mn chelate-1a (0.603g, 0.996mmol) was added, followed by EDCI-HCl (0.473g, 2.47mmol), followed by hydrated HOBt (0.063g, 0.466mmol). The pH was maintained at 6 by adding 1.0M HCl or 1.0M NaOH as required, while stirring at ambient temperature for 7.5 hours. Racemic-3-aminopropane-1,2-diol (0.095g, 1.04mmol) and EDCI-HCl (0.453g, 2.36mmol) were added, and the pH was maintained at 6 while stirring at ambient temperature for 15 hours. The reaction solution was evaporated to dryness in vacuo and heated at C 18 The crude product was purified on silica gel (100% water to 20% AcN in water) to give 0.280 g (41%) of the desired product as a light yellow solid (ESI: m / z = 680 (M+H) + ).

[0088] Embodiment 22 Synthesis of Mn chelate-10 isomer pool A and isomer pool B. Mn chelate-10 was synthesized as described above and 18 The two isomeric pools were separated and isolated on silica gel (100% water to 20% AcN in water) as a light yellow solid (ESI: m / z = 680 (M+H) + ).

[0089] Embodiment 23 Synthesis of Mn chelate-15 (Compound XX).

[0090] Compound XX In a 250 mL 3-neck round-bottom flask equipped with a magnetic stir bar and a pH probe, ethanolamine (5.153 g, 84.4 mmol) was dissolved in H 2 O (50mL). Mn chelate-1a (20.107 g, 37.7 mmol) was added, followed by hydrated HOBt (0.289 g, 1.89 mmol). The pH was adjusted to 6.3 with concentrated HCl, and then EDCI-HCl (16.966 g, 88.5 mmol) was added. The pH was maintained between 6.0-6.5 while stirring at ambient temperature for 2.5 hours. The reaction solution was diluted with water (280 mL) and purified by passing the solution sequentially through an IR-120 (Na) ion exchange column and then an IR-400 (Cl) ion exchange column. The column was then heated to C 18The resulting crude material was purified on silica gel (5% AcN to 20% AcN in water) to give 16.05 g (69%) of the desired product as a light yellow solid (ESI: m / z = 620 (M+H) + ).

[0091] Embodiment 24 Synthesis of Mn chelate-15 isomer pool A and isomer pool B. Mn chelate-15 was synthesized as described above and 18 The two isomer pools were separated and isolated on silica gel (5% AcN to 20% AcN in water) as a light yellow solid (ESI: m / z = 620 (M+H) + ).

[0092] Embodiment 25 General method for measuring r1 and r2 relaxation efficiencies. Manganese-containing chelates were dissolved in water at concentrations ranging from 5-0 mM Mn. T1 and T2 relaxation times were then measured using a Brüker mq60 relaxometer at 60 MHz and 40°C. A linear fit of 1 / T1 or 1 / T2 (in all cases R 2 >0.99) give r1 or r2 values ​​as a function of Mn concentration, respectively.

[0093] Table 1. R1 and R2 relaxation efficiencies in human serum at 60 MHz and 37°C. Compound <![CDATA[r1(mM -1 s -1 )]]> <![CDATA[r2(mM -1 s -1 )]]> Mn chelate-5 6.0 15.4 1:1 mixture of (R,R) & (S,S)-Mn chelate-5 5.9 15.2 (R,S)-Mn chelate-5 6.0 15.4

[0094] Method for evaluating Zn transmetallation. Mn chelate was dissolved in a solution containing 200 mM ZnCl at pH 4. 2 15 mM ammonium formate in an aqueous solution to give a Mn chelate concentration of about 2 mM. The resulting solution was incubated at 40°C with mixing and aliquots were periodically analyzed by HPLC. The percentage of Mn-containing chelate remaining in the solution was measured by integration at 265 nm.

[0095] Method for preparing Mn-54 labeled chelate for biodistribution studies. A 3 mL glass vial equipped with a magnetic stir bar was charged with manganese chelate (1 mg) and 1.0 M ammonium formate, pH = 4 (0.5 mL). 54 MnCl 2(~500 μCi), and the resulting solution was heated at 40°C for 16 hours. The resulting solution was purified via preparative HPLC to remove unchelated Mn. The radioactive fractions were collected and evaporated to dryness in vacuo. The radioactive residue was dissolved in water containing non-radioactive Mn chelate (0.310 M) to prepare ~30 μCi of radioactivity at a dose of 0.620 mmol Mn / kg, with an injection volume of 2 mL / kg.

[0096] General methods for Mn-54 biodistribution studies. The experimental protocol complies with the Guide for the Care and Use of Laboratory Animals and is approved by the institutional IACUC. Female Sprague-Dawley rats (130-150 g) are housed in standard cages, provided with ad libitum access to standard commercial feed and water, and maintained in a room with controlled temperature and humidity under an alternating 12-hour light: dark cycle. Before injecting the Mn-54 labeled chelate, rats are anesthetized via inhalation of 3% isoflurane (EZ Anesthesia Systems). Prepare the injection site with alcohol wipes, and place a temporary 27Ga catheter in the tail vein. ~ 30 μCi of Mn-54 labeled chelate prepared with non-radioactive Mn chelate is injected with an injection volume of 2 mL / kg at a rate of 1 mL / min at a dose of 0.620 mmol non-radioactive Mn chelate / kg. After injection, animals are housed individually in a wire bottom cage lined with filter paper until the first urine blank urine is collected. The rats were then co-housed in standard long-term cages. Seven days after injection, the animals were sacrificed by CO2 immersion, and the organs and tissues of interest were removed and the radioactivity was determined using a Wizard 2480 gamma counter (Table 2).

[0097] Table 2. Injection containing ~30μCi 54 % ID ± SD of tissues 7 days after 0.62 mmol Mn / kg dose of Mn labeled chelate. a LoD = 0.002% ID, n = 4; b LoD = 0.001% ID, n = 4

[0098] Embodiment 26 The dissociation of manganese from manganese chelates in human serum was measured using the following method.

[0099] An aqueous solution of manganese chelate (2 mM, 100 μL) was added to human serum obtained from coagulated blood (Sigma-Aldrich, 1900 μL). The mixture was incubated at 37°C. At a specific time point, an aliquot of 200 μL of the test sample was mixed with saline (400 μL) and analyzed by size exclusion chromatography (equipped with a metal-free HPLC with a column having a separation range of 5000-500000 Daltons) combined with online detection of manganese-containing species by ICP-SF-MS. The dechelation percentage was measured as the area percentage of the high molecular weight (protein) fraction. EDTA solution was flowed through the system at regular intervals to ensure low levels of background metal ions. Human serum was incubated with Mn (II) acetate and injected to identify the position of the Mn-bound component in the high molecular weight region of the chromatogram.

[0100] Fig.10 The chromatographic separation of protein-bound manganese from intact manganese chelates is demonstrated in the slower eluting low molecular weight fraction.

[0101] Four different stereoisomers (RR, SS, SR and RS) of Mn chelate-5 were analyzed in this assay. Table 3 shows the percentage of dechelation measured by quantitative detection of protein-bound manganese at time points of 3, 24 and 49 hours after the start of the experiment.

[0102] Table 3. Percent dechelation of Mn chelate-5 stereoisomers in human serum.

Claims

1. Compounds of formula (I): or a salt or solvate thereof, wherein: Each R 1 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 an aryl, or carbohydrate moiety; Each R 2 Independently selected from C 1-20 Hydroxyalkyl, C 1-6 Alkyl or hydrogen; R 3 Selected from C 1-3 Alkyl or -(CH2) m -C(=O)-NR 5 R 6 , where m is an integer from 2 to 5, where R 5 and R 6 are independently selected from hydrogen, C 1-20 Hydroxyalkyl, C 1-6 alkyl, optionally substituted by one or more selected from halogen and -C(=O)-NH-C 1-6 The substituents of hydroxyalkyl are substituted with C 3-6 an aryl, or carbohydrate moiety; R 4 represents 0-3 selected from hydroxyl, C 1-6 Alkyl and C 1-6 a substituent of the hydroxyalkyl group; and Each n is an integer from 0 to 4; wherein the compound of formula (I) has (R,R) or (S,S) stereochemistry.

2. The compound of claim 1, wherein the compound comprises at least two hydroxyl groups.

3. The compound of claim 1, wherein: i. Each R 1 C 1-20 Hydroxyalkyl; ii.R 3 is methyl; iii.R 2 and R 4 is hydrogen; and iv.n is 2.

4. The compound of claim 1, wherein each R 1 C 1-20 Hydroxyalkyl.

5. The compound of claim 1, wherein R 3 It is methyl.

6. The compound of claim 1, wherein R 2 and R 4 For hydrogen.

7. The compound of claim 1, wherein n is 2.

8. The compound of claim 1, wherein each R 1 Independently for C 3-9 Hydroxyalkyl.

9. The compound of claim 1, wherein each R 1 Independently for C 3-6 Hydroxyalkyl.

10. The compound of claim 1, wherein the compound is:

11. The compound of claim 1, wherein the compound is:

12. A method of imaging a patient, the method comprising administering to a patient in need thereof a compound of claim 1, followed by obtaining an MRI image of the patient.

13. A method of imaging a patient, the method comprising administering to a patient in need thereof a compound of claim 10, followed by obtaining an MRI image of the patient.

14. A method of imaging a patient, the method comprising administering to a patient in need thereof the composition of claim 11, followed by obtaining an MRI image of the patient.

15. A method for enantioselective synthesis of the compound of claim 1, comprising: (a) Monoalkylation of the first enantiomer of 5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate using a compound of formula (III) (b) subsequently alkylating the compound from step (a) with a further amount of the same enantiomer of 5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate; (c) reacting the product of step (b) with Mn; and (d) reacting the product of step (c) with an amino alcohol.

16. A method for enantioselective synthesis of the compound of claim 1, comprising: (a) Monoalkylation of the first enantiomer of (S)-5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate using a compound of formula (III) (b) subsequently alkylating the compound from step (a) with a further amount of (S)-5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate; (c) reacting the product of step (b) with HCl; (d) reacting the product of step (c) with Mn; and (e) reacting the product of step (c) with D-glucosamine.

17. A method for enantioselective synthesis of the compound of claim 1, comprising: (a) Monoalkylation of the first enantiomer of (R)-5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate using a compound of formula (III) (b) subsequently alkylating the compound from step (a) with a further amount of (R)-5-benzyl 1-tert-butyl 2-(methylsulfonyloxy)glutarate; (c) reacting the product of step (b) with HCl; (d) reacting the product of step (c) with Mn; and (e) reacting the product of step (d) with D-glucosamine.

18. A method according to claim 15 or claim 16, wherein the compound is a compound according to claim 10.

19. A method according to claim 15 or claim 17, wherein the compound is a compound according to claim 11.

Citation Information

Patent Citations

  • Manganese chelates and their use as contrast agents in magnetic resonance imaging (MRI)

    WO2011073371A1

  • Chelate compounds

    WO2017220610A1